The proto-oncogene Her2/neu[1] is an attractive tumour antigen for immunotherapy against breast cancer since it is overexpressed in some 20% of all breast cancers and in addition, the transformed phenotype is dependent on its expression. This evidence concerns the gene ERBB2 and breast carcinoma.